Pursuant to Regulation 34(1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 20215 , enclosed please find the copy of Annual Report along with the Notice of Annual ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics has submitted its Annual Report for FY 2024-25 along with the Notice of its 43rd Annual General Meeting, scheduled for August 21, 2025, to be held via video conferencing at 11:00 AM. Ordinary business items include adopting the standalone and consolidated financial statements and re-appointing Executive Director Mr. Cedric Lobo, who retires by rotation. Special business includes revising the related-party transaction (RPT) limit with subsidiary Lensco – The Lens Company for FY 2025-26 from Rs. 9 crore to Rs. 12 crore, approving material RPTs for FY 2026-27, appointing CS Girija Nagvekar as Secretarial Auditor for five years (FY26 to FY30), and approving USD 7,400 per month remuneration for Mr. Gaurav Gupta (relative of CMD K.G. Gupta) as CEO of subsidiary Lensco. The company is also seeking shareholder approval to raise its borrowing and charge-creation limit to Rs. 50 crore, replacing the 2014 limit. The company has not declared any dividend since FY 2010-11.
Routine annual filing with no immediate material impact on share price. Shareholders should note the raised RPT limit with the US-focused subsidiary Lensco signals expected higher business volumes. No dividend has been paid for over 13 years, so income-seeking investors should not expect a change.